Placebo to match SOF

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis CHepatitis C

Phase 3

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

CompletedNCT01542788

Gilead SciencesChronic Hepatitis C

Start: 2012-03-31End: 2013-02-28Updated: 2014-05-19

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

CompletedNCT01604850

Gilead SciencesChronic Hepatitis C

Start: 2012-06-30End: 2013-05-31Updated: 2014-05-28

Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

CompletedNCT01682720

Gilead SciencesHepatitis C

Start: 2012-09-30End: 2014-01-31Updated: 2014-10-09

Related Papers

Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes

The Journal of Infectious Diseases2015-01-1256 citations

Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens

Alimentary Pharmacology & Therapeutics2014-07-1537 citations

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

New England Journal of Medicine2014-05-04796 citations

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

2013-04-23761 citations